PBAC's latest decision on Poly-l-lactic acid: Recommended with restriction (2009). Considered for treatment of facial lipoatrophy caused by therapy for HIV infection.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
$75k/QALY
$15k/QALY–$75k/QALY · across 2 submissions
Submissions
2
first 2008
Submissions
2
2008 → 2009
Eligible population
HIV patients with severe facial lipoatrophy caused by therapy for HIV infection
Therapy area
Other
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
QoL, Social Functioning, Mental Health Component, Anxiety, Depression
Key trials
Carey 2007, Moyle 2004
Comparator
placebo
Economic model
CUA
ICER basis
Range aggregates 2 submissions (2008–2009) — not a single base case.
Submission history
Nov 2008: Not recommended · Authority Required — ICER $45k/QALY
Mar 2009: Recommended with restriction · Authority Required — ICER $75k/QALY